抗程序性细胞死亡-1（anti-PD-1）治疗在复发或难治性经典霍奇金淋巴瘤（cHL）患者中显示出良好的疗效和良好的耐受性。然而，对于在anti-PD-1治疗中取得客观疗效的复发或难治性cHL患者的长期结果数据有限。本研究纳入了来自四个2期临床试验中的260名反应者。中位年龄为32岁，男女比为1.3:1。经过31.1个月的中位随访期，116名（44.6%）反应者出现疾病进展，18名（6.9%）死亡。总体而言，3年无进展生存（PFS）率和总生存（OS）率分别为55.1%和89.7%。与完全缓解患者相比，部分缓解患者的预后较差（3年PFS，29.5% vs. 72.3%，P < 0.001; 3年OS，81.5% vs. 94.4%，P = 0.017）。此外，难治性患者的生存结果较复发患者差。多变量Cox回归分析显示部分缓解和难治性疾病是PFS的独立风险因素。综上所述，在r/r cHL患者中，部分缓解和难治性疾病对抗PD-1治疗的生存益处有负面影响，这凸显了多模态治疗策略的必要性。© 2023. 四川大学华西医院。

Anti-programmed cell death-1 (anti-PD-1) therapies have shown a favorable efficacy and good tolerance for relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). However, there are limited data on long-term outcomes among patients with r/r cHL who achieve an objective response to anti-PD-1 therapies. A total of 260 responders from four, phase 2 clinical trials were included in this study. The median age was 32 years with a male/female ratio of 1.3:1. After a median follow-up period of 31.1 months, 116 (44.6%) responders experienced disease progression and 18 (6.9%) died. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 55.1% and 89.7% overall. Patients with partial remission (PR) had inferior outcomes compared with those who achieved complete remission (3-year PFS, 29.5% vs. 72.3%, P < 0.001; 3-year OS, 81.5% vs. 94.4%, P = 0.017). Moreover, the survival outcome was inferior for patients with refractory disease compared with those with relapsed disease. Multivariate Cox regression analysis showed PR and refractory disease were independent risk factors for PFS. In conclusion, PR and refractory disease have a negative impact on the survival benefit of anti-PD-1 therapeutics in patients with r/r cHL, which highlights the need for multimodal treatment strategies.© 2023. West China Hospital, Sichuan University.